AIM
COGT icon

Aigen Investment Management’s Cogent Biosciences COGT Stock Holding History

Aigen Investment Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,661
Closed -$201K – 572
2025
Q4 		$201K Buy
+5,661
New +$159K 0.05% 479
2025
Q3 		– Sell
-33,784
Closed -$243K – 839
2025
Q2 		$243K Buy
+33,784
New +$187K 0.03% 600
2024
Q2 		– Sell
-17,822
Closed -$120K – 815
2024
Q1 		$120K Buy
+17,822
New +$110K 0.03% 597

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Aigen Investment Management's COGT Position: Q1 2026 in Review

Aigen Investment Management sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 5,661 shares — an estimated $201K sold.

Aigen Investment Management first reported a position in COGT in Q1 2024 and held it in 3 quarters. The position peaked at $243K in Q2 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Aigen Investment Management reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
  • Aigen Investment Management sold 5,661 Cogent Biosciences shares in Q1 2026, an estimated $201K.
  • Aigen Investment Management first reported a position in Cogent Biosciences in Q1 2024 and held it in 3 quarters.
  • Aigen Investment Management's Cogent Biosciences position peaked at $243K in Q2 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Aigen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.